Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649755 | 0.87 | PPARG (0.49) | PPARGNR3C1EGFRALDH1A1CNR1 | |
| SCHEMBL6649483 | 0.87 | HTR2C (0.47) | HTR2CHTR2BHTR2APPARG | |
| SCHEMBL6647575 | 0.83 | NPC1 (0.45) | NR3C1EGFRALDH1A1CNR1KDM4E | |
| SCHEMBL6647632 | 0.82 | HTR2C (0.47) | HTR2CHTR2BHTR2AALDH1A1KDM4E | |
| SCHEMBL6645987 | 0.81 | CNR1 (0.50) | NR3C1EGFRALDH1A1CNR1KDM4E | |
| SCHEMBL6502096 | 0.80 | GCGR (0.49) | HTR2CHTR2BHTR2APPARGNR3C1 | |
| SCHEMBL6644225 | 0.79 | KDM4E (0.44) | NR3C1EGFRALDH1A1CNR1KDM4E | |
| SCHEMBL6646168 | 0.76 | NR3C1 (0.41) | NR3C1EGFRALDH1A1CNR1KDM4E | |
| SCHEMBL6497088 | 0.75 | HTR2C (0.51) | HTR2CHTR2BHTR2ANR3C1 | |
| SCHEMBL6645220 | 0.74 | NR3C1 (0.39) | NR3C1EGFRALDH1A1CNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | HTR2C 1349/4885HTR2B 485/4885HTR2A 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.